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Abstract
The nitric oxide (NO) sibling, nitroxyl or nitrosyl hydride (HNO), is emerging as a molecule whose pharmaco-
logical properties include providing functional support to failing hearts. HNO also preconditions myocardial
tissue, protecting it against ischemia-reperfusion injury while exerting vascular antiproliferative actions. In this
review, HNO’s peculiar cardiovascular assets are discussed in light of its unique chemistry that distinguish HNO
from NO as well as from reactive oxygen and nitrogen species such as the hydroxyl radical and peroxynitrite.
Included here is a discussion of the possible routes of HNO formation in the myocardium and its chemical
targets in the heart. HNO has been shown to have positive inotropic/lusitropic effects under normal and con-
gestive heart failure conditions in animal models. The mechanistic intricacies of the beneficial cardiac effects of
HNO are examined in cellular models. In contrast to b-receptor/cyclic adenosine monophosphate/protein kinase
A-dependent enhancers of myocardial performance, HNO uses its ‘‘thiophylic’’ nature as a vehicle to interact with
redox switches such as cysteines, which are located in key components of the cardiac electromechanical machinery
ruling myocardial function. Here, we will briefly review new features of HNO’s cardiovascular effects that when
combined with its positive inotropic/lusitropic action may render HNO donors an attractive addition to the
current therapeutic armamentarium for treating patients with acutely decompensated congestive heart failure.
Antioxid. Redox Signal. 14, 1687–1698.
Introduction
Nitroxyl or nitrosyl hydride (HNO) is the oneelectron-reduction product of nitric oxide (NO) (25),
which displays a distinctive chemistry from NO (25), but
whose role has yet to be fully determined. HNO was the first
molecule found in the interstellar clouds to contain a N =O
bond (71) (where it appears to be particularly abundant).
Further, it was nearly two decades ago that investigators
suggested that HNO may have cardiovascular effects and
may ultimately account for the mechanism of endothelium-
derived relaxing factor (EDRF) (24). More recently, HNO has
also been suggested to be a mechanism for endothelial-
derived hyperpolarization (2). However, despite the fact that
the presence of HNO may span from the heavens to the heart,
research dedicated to HNO would not be one which we would
call a burgeoning field. One plausible explanation for the
limited attention accorded to HNO, so far, is the lack of evi-
dence for its in vivo generation. However, this limitation is
likely technical in nature and may not be a true biological
limitation. Currently, there are no definitive methods available
to unequivocally detect the ‘‘footprints’’ of HNO in a biological
system. HNO is different from NO and some oxygen-derived
redox-active species, in that it is not a ‘‘radical,’’ thus it cannot
be directly trapped by electron paramagnetic resonance/
electron spin resonance–based methods. Moreover, the use of
currently available HNO donors in biological buffers leads to
the very short half-life (2.7 min) of this purported gaso-
transmitter (45), rendering HNO a rather ‘‘fleeting’’ species.
Hence, this caveat prevents us from speculating about its
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physiological relevance. Nonetheless, given the strikingly
different functional outcomes produced by HNO versus NO
or other reactive nitrogen species (RNS) such as nitrite (35) and
peroxynitrite (32), we are free to consider HNO donors as
pharmacological tools for treating several disorders, especially
cardiovascular diseases. In this review, we will first describe
possible routes through which HNO may be generated in the
myocardium as well as its chemistry and putative targets
within the contractile machinery. Then, we will describe in
detail the ability of HNO to improve myocardial function,
focusing on myocardial mechanics, both in vivo and in vitro, in
normal and failing hearts. The intriguing vascular effects of
HNO donors will not be addressed here, as these are the
subject of a fully dedicated article also in this Forum Issue.
Finally, we will illustrate how the distinctive redox chemistry
and putative signaling pathways of HNO can represent a valid
alternative or an advantageous addition to the current thera-
peutic mainstays for treating congestive heart failure (CHF) of
ischemic or nonischemic origin.
HNO in the Heart: Possible Sources, Chemical
Targets, and Ways of Detection
In vitro evidence of HNO generation
The endogenous generation of HNO remains speculative.
Thus, it is currently unknown whether HNO is a gastro-
transmitter akin to other endogenously synthesized small
molecules such as NO, carbon monoxide (CO), or hydrogen
sulfide (H2S). Equally unknown is whether HNO has a sig-
naling capacity similar to low levels of hydrogen peroxide.
HNO was detected in interstellar space more than 30 years
ago (71), and an abundance of in vitro evidence supports its
possible existence in biologically relevant systems. Moreover,
as we will learn later, in several settings, the actions of HNO
are potent, very selective, and fast in both the onset and offset.
If ‘‘nature operates in the fastest way possible’’ (Roger Bacon,
Opus Maius), then it is plausible that HNO is one of nature’s
messengers; however, its endogenous generation remains
hypothetical.
Putative pathways for the generation of HNO in vivo have
been developed that are either dependent or independent of
the enzyme nitric oxide synthase (NOS). NOS functions
through the conversion of L-arginine to NO and L-citrulline
and in the process consumes O2 and NADPH while utilizing
the cofactor tetrahydrobioterpin (BH4). However, this process
also produces the intermediate compound, NG-hydroxy-L-
arginine (NOHA), in the oxidation of arginine, as well as
peroxide and superoxide (O2
 - ) when it is in its uncoupled
state (induced by the absence of either arginine or BH4). One
possible mechanism for the NOS-dependent synthesis of
HNO is through the direct oxidation of NOHA when NOS is
uncoupled (24, 59). In turn, HNO can be converted to NO
through the reaction of Fe(II) at the heme site of the enzyme or
via superoxide dismutase (28, 62). HNO can also be produced
by the catalysis of arginine to citrulline in the absence of
BH4 (1) (Fig. 1).
In addition to these NOS-dependent mechanisms, there are
also a number of possibilities for the NOS-independent for-
mation of HNO. However, these mechanisms suffer from the
limitation that unlike O2
 - and O2, HNO cannot be formed
through the direct reduction of NO to HNO due to energetic
barriers (this is also highlighted by the fact that the conversion
of HNO to NO requires the use of a metal catalyst). The
mechanisms by which HNO can be formed include the de-
composition of nitrosothiols (74), the dismutation of NO into
nitrosonium (NO + ) and HNO (65) (catalyzed by iron sulfur
complexes), or the reduction of NO by xanthine oxidase (61).
As with the enzyme nitrite reductase, there is also the possi-
bility of a reduction of coordinated NO + to NO and NO- ,
which has been recently re-evaluated (36).
Interestingly, Yong et al. have suggested that HNO may be
generated by a mechanism involving the interaction of H2S
with NO. This is based on the observation that when a H2S
donor (NaHS) is combined with an NO donor (sodium
nitroprusside) in isolated rat ventriculocytes, cellular con-
traction was increased in a manner closely reminiscent of the
actions of HNO (78). One possible mechanism by which this
could occur is that HS - acts as a nucleophile, attacking the
Fe nitrosyl bond of sodium nitroprusside forming an S-NO
intermediate that decomposes through the reaction with SH-
to give HNO.
There are additional pathways that do not implicate the
generation and interconversion of nitrogen oxides in HNO
formation. One is through the heme protein mediated oxida-
tion of hydroxylamine (NH2OH) in the presence of peroxide
(16). This is a particularly intriguing biomediator, as it involves
the possible cyclic production of HNO involving peroxide,
thiols, and NH2OH. When HNO is initially formed, it can react
with thiols such as glutathione (GSH), which results in
NH2OH. In the cell, there is between 2 and 5 mMGSH, making
it a primary target of HNO and a primary and decomposition
product of NH2OH. As just stated, NH2OH in the presence of
peroxide and heme protein can generate HNO. This forms a
cycle that under oxidative conditions can generate HNO, thus
providing a recycled supply of this molecule. However, this
mechanism would be limited if there was a breakdown in
disulfide reduction. This mechanism is especially interesting,
as it suggests a possible endogenous pathway by which sig-
naling molecules such as hydrogen peroxide and the oxy-
genated derivative of ammonia may lead to HNO formation.
In the end, there are numerous possible mechanisms for
HNO formation at least in vitro, and the recent evidence
showing that endogenous molecules can act as substrates for
HNO formation renders its endogenous biosynthesis even
more likely. The exact connotations of each one of these routes
remain to be verified in vivo.
HNO targets
HNO has specific targets that do not react with either NO
nor CO. Specifically, HNO will react with higher oxidation
state metals [i.e., Fe(III), Cu(II), and Mn(III)] as well as thiols
(25). Utilizing the affinity of HNO for ferric heme proteins,
methods using the reductive nitrosylation of Mb(III) to form
the nitrosyl complex in solution and xerogels have been used
to detect HNO, distinguishing it from NO (15). As such, HNO
can affect key metalloproteins by either activation (e.g., soluble
guanylyl cyclase [sGC]) or inhibition (e.g., peroxidases and
monoxygenases like cytochrome P450) (48). Thus, metal-based
reactions carried out by HNO may be important in different
signaling pathways that differ from those of NO and CO.
The most unique effect of HNO, and what substantially
differentiates it from NO, is its reactivity with thiols. Thiols
are major targets for HNO, which can lead to reversible and
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potentially irreversible modifications. These are particu-
larly important residues, as mounting evidence supports
the notion that thiol(-SH)-based switches (chiefly via post-
translational modification of cysteine residues) can control
several cellular functions. Typically, a ‘‘redox switch’’ consists
of two redox-sensitive cysteine residues and the disulfide
bond between them. The possibility that two cysteines
are oxidized to form a disulfide bond depends not only on the
topology but also on the temperature- and pH-dependent
redox potential of cysteine-cystine (49). As shown in Figure 2,
HNO can modify cysteines in two distinct ways. The first is via
its direct targeting of reactive thiols in cysteine residues to
form N-hydroxysulfenamide (RSNHOH). Second, if there is
an additional available thiol in the vicinity, a disulfide bond
may form (36). The possible signaling role of sulfenamide
formation remains to be fully ascertained, that is, whether this
post-translational modification is always irreversible and
coupled to pathologic structural and function changes. Con-
versely, it is increasingly evident that, under mild oxidizing
conditions, the appearance of inter- and/or intradisulfide
bonds often leads to a change in protein function, due to a
conformational change that may or may not implicate an
oligomer transition (49). Then, these modifications are re-
versed by cellular reducing factors belonging to the Trx and
GSH systems, with or without transformation of the oligo-
meric state that accounts for the change in protein function
(49). When it comes to HNO, this type of reversible post-
translational modifications may have functional relevance as
we will see when discussing HNO-induced modifications in
isolated cardiac myocytes and muscles.
Interestingly, it has been widely reported that HNO may
modify thiols despite the presence of high concentrations
of low-molecular-weight thiols (e.g., GSH) (12, 34, 40). The
affinity of HNO for GSH and formation of the adduct GSH
sulfinamide has been used to determine the presence of HNO
in chemical and biochemical models (17, 29, 66). Since GSH
has a concentration within the millimolar range inside the
intracellular compartment, it should be one of the major re-
actants resulting in little additional modifications (i.e., protein
modification). However, HNO does have a profound effect on
cellular signaling, thus suggesting that the ability of HNO to
modify a given thiol depends on other biochemical reasons
such as its acid dissociation constant (pKa) or location within
the cell (e.g., a hydrophobic subcellular compartment). When
the pKa of a particular thiol is very low, the reactivity of this
FIG. 1. Possible nitric oxide synthase (NOS)-dependent
pathways leading to the in vitro formation of nitroxyl or
nitrosyl hydride (HNO). In addition to the direct oxidation of
NG-hydroxy-L-arginine (NOHA) when NOS is uncoupled
and to the possibility of generating HNO via tetrahydro-
bioterpin (BH4)-free NOS, the lower part of the diagram
highlights the possibility of forming HNO from the decom-
position of S-nitrosothiols. (To see this illustration in color the
reader is referred to the web version of this article at
www.liebertonline.com/ars).
FIG. 2. Reactive oxygen spe-
cies (ROS) and HNO interac-
tion with thiols. Thiols, and in
particular reactive cysteines, are
subjected to a continuum of
modifications by ROS and
HNO. HNO can modify cyste-
ines in two distinct ways. The
first is via its direct targeting of
reactive thiols in cysteine resi-
dues to form N-hydroxy-
sulfenamide (RSNHOH).
Second, if there is an additional
available thiol in the vicinity,
a disulfide bond may form.
Whether the formation of sulfe-
namide always leads to irre-
versible and likely pathological
signaling remains to be fully es-
tablished. Conversely, it is plau-
sible that HNO acting as a mild
oxidizing agent promotes the
formation of reversible inter-
and/or intradisulfide bonds that
ultimately leads to changes in
protein function (see also text).
(To see this illustration in color
the reader is referred to the web
version of this article at
www.liebertonline.com/ars).
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site for HNO will out-compete the presence of excess GSH.
One well-suited example is glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), which is in the cytoplasm and in-
hibited by HNO despite the presence of GSH (40) due to the
high reactivity of its reactive cysteine residue.
As mentioned, it is interesting that HNO can function in the
face of high levels of additional thiols in the form of GSH.
HNO would not sail too far in cellular microdomains in which
GSH is particularly abundant. This evidence leaves many
questions open, such as how HNO travels in the bloodstream
that is full of thiols such as GSH, cysteine, cysteinyl-glycine,
and homocysteine, both at plasma and whole blood level.
When it comes to intracellular compartments such as in-
tramyocyte environment, in addition to its reactivity, the lo-
cation of a cysteine containing protein in the cell is also an
important consideration. HNO is hydrophobic in nature;
thus, it is plausible that it can preferentially find its targets in
hydrophobic regions. GSH typically does not exist in these
regions and as such, HNO will be more likely to react with
thiol or metal containing proteins in these hydrophobic re-
gions than in subcellular citadels filled with GSH (36).
Therefore, the pKa of a given cysteine and the location of the
molecular target are likely to ‘‘compartmentalize’’ the reactivity
of HNO, thereby conferring to it a specificity of action. Tyrosine
hydroxylase and NF-jB are additional interesting examples of
possible HNO targets, because they harbor a low pH key
cysteine whose modifications may drive changes in function.
In the heart, it is possible that key protein residues located
in functionally relevant structures of the contractile machin-
ery contribute to intracellular cardiac control of Ca2 + cycling/
handling and myofilament response to Ca2 + , positively
modulating rather than countering overall myocardial per-
formance. As will be discussed later, this eventuality is likely
the outcome of ‘‘selective’’ targeting operated by reactive
oxygen species (ROS)/RNS on critical, redox-sensitive pro-
tein residues, chiefly cysteines, containing highly reactive
thiols. Hence, the biochemical ground for HNO pharmaco-
logical actions, as well as a palette of possibilities by which
HNO reactivity toward thiols is seen, is ultimately different
from other well-known oxidizing agents.
In Vivo Cardiovascular Action of HNO Donors
HNO donors
For biological studies, many HNO donors are currently
available (47), but not all of these are amenable for in vivo
or even in vitro studies. The most commonly used HNO-
releasing agents for animal studies are the prototypic
HNO donor Angeli’s salt (AS, Na2N2O3) (45), Piloty’s acid
(PhSO2NHOH), and its derivatives, isopropylamine- NO

(IPA/NO) (48) and acyloxy nitroso compounds such as 1-
nitrosocyclohexyl acetate (NCA, also known as the ‘‘blue
compound’’) (63). Without a doubt, AS remains the most
widely used HNO donor despite its short half-life and the
well-known downside of being a coreleaser of NO2
- (which
requires the use of proper controls to exclude its possible
confounding effects).
HNO in normal in vivo hearts
Initially, HNO donors such as AS and Piloty’s acid have
attracted attention as vasodilating substances. Fukuto et al.
were the first to report that, in both rabbit aorta and bovine
intrapulmonary artery, AS/HNO relaxes vessels by a sGC-
dependent mechanism (24). Since then, several studies have
explored the modalities by which AS, Piloty’s acid, and its
derivatives relax vessels, both in vitro and in vivo. The total or
partial sGC-dependency of HNO vasodilation and more, in
general, the way by which HNO vasorelaxes both capacitance
and resistance vessels is the subject of an extensive review in
this forum issue (7).
In addition to its vascular effects, HNO exerts a unique
in vivo action on contracting myocardium. Differently from
other NO donors, which result in a modest or clearly neg-
ative impact on contractile function [particularly when in
excess (43), HNO donors promptly and markedly increase
myocardial contractility (positive inotropy) while accelerat-
ing relaxation (positive lusitropy)]. Using conscious dogs
instrumented for pressure–volume relationships (an ap-
proach that allows the dissection of primary direct effects on
the myocardium versus cardiac changes due to modified
vascular loading conditions) (32, 33), our group was the first
to demonstrate that AS/HNO (10 lg/kg = 0.082lmol/kg for
10–20 min, intravenously) increases intrinsic ventricu-
lar stiffness, independent from changes in cardiac volumes.
In addition, HNO hastens ventricular relaxation and unloads
the heart (55). All these effects persist after both left ven-
tricular (LV) volume repletion—to match baseline filling
volumes—or after autonomic blockade with hexamethoni-
um—to offset possible confounding effects deriving from
baroreflex activation. The modalities of HNO cardiac actions
neatly distinct from those of well-known inotropic agents
such as b-agonists or phosphodiesterase inhibitors have been
confirmed, showing that the AS/HNO effects in conscious
dogs are not offset by sustained b-adrenergic blockades. The
unique combination of positive inotropy and preload re-
duction, in conjunction with a balanced veno- and arterial
dilation, cannot be mimicked by donors of NO, nitrate, or
other RNS such as peroxynitrite (32). In addition, the HNO-
evoked rise in function is fully prevented by the thiol-do-
nating compound N-acetyl-L-cysteine. L-cysteine has been
used to discriminate between in vitro aortic relaxations to
HNO and NO (58). This suggests that when the intracardiac
environment is enriched with free floating thiols, the ability
of in situ thiols to react with HNO is reduced, thereby
blunting its effect.
HNO in failing hearts
CHF is a chronic disease condition in which ROS and RNS
are generated by multiple sources (52), possibly leading to a
reduced bioavailability of NO. In addition to decreased an-
tioxidant defenses, the reduction in NO can result in a further
increase in ROS due to the uncoupling of NOS. The conse-
quent tissue redox imbalance can result in key events deter-
mining or associated with the onset and progression of the
CHF disease. These include altered excitation-contraction
(EC) coupling, cardiomyocyte maladaptive hypertrophy, ex-
tracellular matrix remodeling, abnormal tissue energetics, loss
in viable myocardium, vascular and capillary alterations, and
inflammation.
Further to this, we should consider that the b-adrenergic
system (which adjusts cardiac force development to increased
work demand) is downregulated in CHF due to b-receptor
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desensitization and uncoupling to their signaling molecules
(18). Increased emission of ROS/RNS may further dampen
this b-agonist stimulated contractile reserve and relaxation
(directly or indirectly) by either altering the b-agonists per se
(32) or negatively interacting with their associated signaling
pathways. For instance, endogenous NO and nitrates are
known to attenuate the response of b-adrenergic stimulation
in both experimental and human CHF (43). This effect rep-
resents a major drawback when a combination of b-agonists
and unloading agents is desired in aiding patients with CHF.
Thus, inotropic/lusitropic agents that do not lose their effi-
cacy in the CHF setting nor display a facile reaction toward
ROS/RNS should be ideal to treat patients with acutely de-
compensated heart failure.
Using the approach just described (i.e., conscious dogs in-
strumented for studying the pressure–volume relationship),
we were able to show that in dogs in whom CHF was induced
by tachypacing (33), HNO donors such as AS improve both
contractility and relaxation to a similar extent as in control
preparations (54). Further, when HNO was administered
concomitantly with b-agonist mimetics such as dobutamine,
they were additive in supporting myocardial contraction as
opposed to NO/nitrite that blunted dobutamine-induced
enhancement in function.
From a signaling point of view, there was an initial
contention that HNO inotropy could be mediated by the
release of calcitonin gene-related peptide (CGRP) from
nonadrenergic/noncholinergic fibers. CGRP is a neuropep-
tide endowed with several, important pharmacological prop-
erties. In the cardiovascular system, CGRP is a potent
vasodilator and induces positive cardiac inotropy in several
species including humans (3). The credence that CGRP could
mediate HNO inotropy was based on the fact that HNO en-
hancement in contractility in vivo can be blocked by the CGRP
receptor antagonist (CGRP8-37) (55) and evidence which
showed that in vivo HNO infusion leads to increased systemic
levels of CGRP (54). However, subsequent studies in normal
and CHF dogs showed that CGRP-induced inotropy is es-
sentially indirect, as it is mediated by the release of norepi-
nephrine from sympathetic efferent fibers and as such is fully
prevented by b-blockers such as timolol (33). That HNO and
CGRP-evoked inotropes diverge in terms of signaling is fur-
ther borne out by the evidence that CGRP stimulatory action
is lost in CHF preparations (33), in keeping with the well-
known downregulation of the b-receptor mediated signaling
in this syndrome (18). Thus, although CGRP release might,
in part, explain HNO-induced vasodilation (21), it defi-
nitely does not account for HNO-evoked positive inotropy-
lusitropy. This realization prompted further in vitro studies
that aimed at dissecting the mechanism(s) of HNO’s action.
From a pharmacological point of view, HNO effects are
not specific to AS, but it instead represents only one of the
many HNO donors that are likely to constitute a new class of
compounds. This contention has been subsequently proved
by the use of IPA/NO (46) (a HNO donor that is chemi-
cally unrelated to AS) as well as of the use of the ‘‘blue com-
pound,’’ NCA (63). One promise of HNO is that its cardiac
action is fully preserved in CHF preparations in face of altered
tissue and vascular redox conditions. In addition, there is
also evidence gathered by the Kemp-Harper’s group which
showed that the in vitro action of HNO is resistant to both the
development of tolerance and scavenging by superoxide
(O2
- ) (7). In essence, these in vitro findings are not ‘‘radical’’
and are fully consistent with the HNO chemistry and with
previous in vivo studies in which it was demonstrated that
repeated infusions, AS/HNO, did not lead to any loss in
efficacy (55).
HNO in ischemia-reperfusion injury
One of the first in vivo studies (if not the very first) to em-
ploy AS as a HNO donor was a report from Ma et al. in which
the impact of AS and the NO donor S-nitrosoglutathione
(GSNO) were compared in rabbits subjected to 45 min of re-
gional myocardial ischemia followed by 180 min of reperfu-
sion (41). The use of GSNO 5 min before reperfusion markedly
attenuated reperfusion injury, as evidenced by an improve-
ment in myocardial function, reduced infarct size and de-
creased activity of creatine kinase (CK) and myeloperoxidase.
Conversely, the administration of hemodynamically equief-
fective doses of AS (3 lmol/kg for 20–30 min) aggravated
reperfusion injury as indicated by increased necrotic size,
CK release, and end-diastolic pressure. It is possible that the
ability of HNO to recruit neutrophils may have had some part
in the detrimental effect of AS on reperfused myocardium
(72). However, the mechanistic underpinnings of this nega-
tive impact still await clarification, and equally relevant is the
possibility of a dose dependency of the effects. Indeed, the
authors found that 1 lmol/kg AS did not significantly affect
the extent of ischemia-reperfusion injury. Although these AS
concentrations widely exceed those used later in in vivo dogs
(54, 55), this article also suggests the need of conducting full-
scale dose-response studies, particularly in light of subse-
quent studies showing that AS given before ischemia is a good
early preconditioning-like agent in isolated and perfused rat
hearts (53). Indeed, Pagliaro et al. reported a few years later
that, in rat hearts, AS/HNO intracoronary infusion (1lM,
final concentration in the heart for 19 min) before 30 min of
global ischemia (and reperfusion) grants a protection similar
to that afforded by classical ischemic preconditioning. The
magnitude of AS-evoked protection cannot be achieved with
equimolar amounts of the NO donor diethylamine/NO
complex (DEA/NO), which has a similar half-life and in vitro
kinetics as AS (46). Coinfusion in the triggering phase of AS
and the HNO scavenger, N-acetyl-L-cysteine (4 mM), com-
pletely reversed the beneficial effects of AS, both at 30 and
120 min of reperfusion. These data suggest that (as in other
settings) HNO is sensitive to the actions of thiol-donating
compounds and likely follows a signaling pathway different
from that of NO. Preliminary studies conducted by our
group showed that in isolated rat hearts, as opposed to DEA/
NO, HNO protection via either AS or IPA/NO cannot be
prevented by the mitochondrial K(ATP) channel (mKATP)
blocker 5-hydroxydecanoate (42). However, very recently
Queliconi et al. have shown that in isolated mitochondria,
HNO (from AS) inhibits complex II and opens mKATP, show-
ing that HNO protects cardiomyocytes against ischemia/
reperfusion injury in an mKATP-dependent manner (60). Ad-
ditional studies to further dissect the protective signaling cas-
cade(s) triggered by HNO given before ischemia are required.
Moreover, it would be of interest to establish whether and how
HNO interacts with other gas-transducing systems such as CO,
H2S, and, of course, NO
 to affect mitochondrial function and
eventually protect the heart. Finally, it is worthwhile to firmly
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establish whether HNO is always (i.e., at any dose) detrimental
at reperfusion and why this may be the case. HNO might
worsen cerebral ischemia-reperfusion injury by increasing
oxidative stress and decreasing brain perfusion (10). Never-
theless, it is difficult to draw definitive conclusions from these
studies entailing different experimental approaches (i.e., in-
jection vs. intravenous infusions), animal species, and possibly
HNO doses.
HNO Effects on Isolated Cardiac Myocytes
Redox-dependent control of E-C coupling
In ventricular cardiac cells, the release of Ca2+ from the
sarcoplasmic reticulum (SR) is a key event in the EC coupling
process. For any given heart beat, a small amount of Ca2+
enters via the sarcolemmal voltage-dependent Ca2+ channels
(L-type Ca2+ channels), which triggers the release of a bigger
pulse of Ca2+ from the SR through specialized Ca2+ -gated
channels (i.e., ryanodine receptors [RyR2]). This event, known
as Ca2+ -induced Ca2+ release, makes Ca2+ available to the
myofilaments and their regulatory proteins, resulting in myo-
filament sliding and ultimately sarcomere contraction. At the
end of each systolic phase, Ca2+ is pumped back into the SR via
the ATP-dependent SR Ca2+ -ATPase (SERCA2a) or excluded
from the cell by the Na+ -Ca2+ exchanger. The function of
SERCA2a is regulated by the reversible inhibitor phospho-
lamban (PLN). b-adrenergic stimulation via cyclic adenosine
monophosphate (cAMP)/protein kinase A (PKA)-mediated
signaling may alter the phosphorylation status of L-type Ca2+
channels, RyR2, PLN, and myofilament regulatory proteins,
thus modifying the function of these key E-C components. For
instance, b-agonist-induced, PKA-mediated phosphorylation
of PLN leads to the removal of its inhibitory effect on SER-
CA2a, thus accelerating the rate of Ca2+ uptake into SR.
In the heart, both acute and chronic exposure to b-adren-
ergic stimulation may result in ROS production (80). This is
important, because PKA, PKG, or PKC phosphorylation is
not the sole modulatory mechanisms for the EC machinery
(i.e., channels, pumps, transporters, and contractile and reg-
ulatory proteins). These structures also harbor critical sulf-
hydryl groups, mainly in the form of cysteine residues that
form the basis of redox reactive ‘‘switches’’ which are sus-
ceptible to a continuum of chemical modifications from en-
dogenous signaling molecules such as NO, RNS, or ROS (75).
These molecules are continuously produced during muscle
contraction and modulate the mechanical properties of mus-
cles such as contraction and relaxation (44). For example, NO
is likely a key mediator in the increase in SR-Ca2 + release after
mechanical stretch (57).
The interplay between ROS/RNS and reactive cyste-
ine residues may span from S-nitrosylation to permanent
irreversible modifications such as carbonylation. Post-
translational modifications, such as S-nitrosylation, can alter
a protein’s function as demonstrated by the increased prob-
ability of the RyR2 channel being in the ‘‘open’’ state after
modification [reviewed in Ref. (44)]. It has been postulated
that hyper-reactive cysteine (Cys) moieties may represent
biochemical components of a more complex ‘‘redox sensor’’
that conveys information about localized changes in redox
potential produced by physiologic (NO) and pathophysio-
logic (quinones, ROS) channel modulators to the Ca2 + release
process (56). Nevertheless, the presence of strong oxidants or
the persistence of oxidative stress results in an altered redox
balance that permanently modifies these same structures. For
instance, in failing hearts, the RyR2 has an increased number
of oxidized thiols; and treating failing myocytes with antiox-
idants significantly improves intracellular Ca2 + handling in
these cells (67). Likewise, L-type Ca2 + channels can be mod-
ified in a redox-dependent manner (likely through cysteine
alterations), thereby increasing Ca2 + influx through the
channel and increasing its intracellular levels (30). In a similar
manner, abundant evidence in intact muscle or myofibrillar
preparations has demonstrated that oxidation of myofilament
proteins results in contractile dysfunction. For instance,
Canton and coworkers have reported that oxidative modifi-
cations at tropomyosin occur in a microembolization-induced
model of CHF in dogs (8). That sulfhydryl groups are critically
involved in myocardial dysfunction of different etiology is
also suggested by a recent study which reported the oxida-
tion of cysteine residues in myosin light chain 1 and actin after
treatment with the oxidizing agent, 2,2’-dithiodipyridine,
at concentrations which cause a reduction in contractile
function (27).
From all these findings, it manifests that (i) ROS/RNS are
major endogenous modulators of basal and b-agonist stimu-
lated contractility via key redox switches; (ii) the concentra-
tion of the reagent used, the length of exposure, and the nature
of the chemical reaction the reagent undertakes with sulfhy-
dryl groups are the primary factors to determine the ultimate
functional outcome (56); (iii) similar to any other excitable
cells, myocytes maintain their intracellular milieu under
tightly controlled reducing conditions to avoid local changes
in redox potential that would ultimately affect the redox sta-
tus of channels harboring hyper-reactive sulfhydryl groups,
thereby leading to their spontaneous opening (76).
Effects of HNO on E-C coupling
When in vitro, ‘‘the reaction of a protein with a modified
cysteine residue is determined by the overall condition of the
protein, including the spatial position of the cysteine residue,
electrostatic interaction between the cysteine residue and
other charged residues, spatial interactions between the cys-
teine residue and a chemical compound, electrophilicity of the
chemical compound, and the pH of the solution’’ (50). From
this statement, it is evident that as a thiophylic agent, HNO
may represent the ideal candidate for a facile reaction with
cysteine residues aligned with key redox active sensor sites in
the myocardial contractile machinery.
Recently, we (35, 69) and others (38, 78) have shown that
HNO donors, such as AS, enhance the function of isolated
rodent (mouse and rat) myocytes, such that they have an in-
creased shortening capacity and an accelerated relaxation
with an increased whole Ca2 + transient. The latter effect
seems to be entirely dependent on HNO-induced stimulation
on RyR2, due to enhanced SR Ca2 + fractional release (69)
without recruiting extracellular Ca2 + from L-type channel
activity (35). Indeed, HNO increases the open probability of
the Ca2 + release channels in RyR2 reconstituted in lipid by-
layers and the Ca2 + spark frequency without altering other
characteristics of these functional units such as coordination
and termination. NO donors (69) or nitrite (35) cannot re-
produce these effects. Similar stimulatory action from HNO
was also described for skeletal Ca2 + release channels (RyR1)
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(9). In both cases (i.e., RyR2 and RyR1), the effects were
reversible on the addition of a sulfhydryl reducing agent,
dithiothreitol, suggesting that HNO targets hyperactive cys-
teine groups in these channels.
Although there was an increase in Ca2 + release after AS/
HNO treatment, the induced inotropy was sustained. This
suggested that the SR should be continuously replenished
with Ca2 + via a HNO-dependent pathway stimulating the
activity of SERCA2a. This is indeed the case, as it has been
determined that HNO activates SERCA2a in a manner that
resembles b-adrenergic/PKA-dependent removal of inhibi-
tion exerted by PLN (69). However, the modality of HNO
activation of SERCA2a is different from those elicited by b-
agonists. Froehlich et al. found that when the three cysteines
present in PLN transmembrane domain are replaced with
alanine, the stimulatory action of HNO is lost (23). Hence,
thiol modification is pivotal in explaining the cardiac stimu-
latory action of HNO.
In the specific case of the PLN/SERCA2a interaction, HNO
likely configures the formation of a ‘‘forbidden disulfide’’
between the cysteines of the PLN transmembrane domain
forming a cross-link in the secondary structure where, for
spatial reasons, a disulfide should not exist (in theory) (75).
This hypothesis, and whether HNO cardiac action requires
the presence of PLN and/or involves additional changes
within the cysteine residues present in SERCA2a, as recently
suggested (38), warrants further investigation. Moreover,
additional studies are needed to establish whether HNO al-
ters SERCA2a conformational flexibility in the presence of
PLN. Finally, HNO functioning as a ‘‘Ca2 + cycling enhancer’’
(Fig. 3) could be particularly prominent in rodents whose
intracellular Ca2 + availability depends almost exclusively on
SR Ca2 + content, but less in species such as humans in whom
extracellular Ca2 + is more important.
HNO also acts at the myofilament level to enhance cardiac
function (Fig. 3). When directly applied to isolated intact
cardiac muscle (right ventricular trabecuale), HNO enhances
myofilament responsiveness to Ca2 + , augmenting myocar-
dial contractility more than whole Ca2 + transients (13), thus
suggesting that HNO also functions as a Ca2 + sensitizing
agent. Again, altering intracellular redox conditions with di-
thiothreitol prevented HNO-induced augmentation in muscle
force development, consistent with the idea that HNO has
affinity for strategically located thiols (13). Mapping these
residues, either at myofilament or at the regulatory protein
level, is an ongoing effort in our laboratory. Since the influ-
ence of HNO on myocyte mechanical properties is fully cyclic
guanosine monophosphate (cGMP)- and cAMP-independent
(69, 78), this highlights a new, redox-dependent way by which
cardiac force generation can be enhanced. The fact that HNO
action appears to be preserved in failing myocytes (68) or in b-
adrenergic desensitized ones (20) hints to the intriguing pos-
sibility that the targets of HNO are ‘‘protected’’ thiol residues,
not readily available to general oxidants and are still available
for redox modifications in face of the overall oxidized envi-
ronment that characterizes failing cardiac cells (52).
Of interest is the possibility that HNO’s interaction with
structures in the EC coupling machinery suggest a possible
interrelationship between HNO and neuronal NOS (nNOS).
As discussed earlier, HNO can be generated by uncoupled or
BH4-free nNOS (1). Since nNOS has been shown to be con-
tiguous to RyR (77), this is a plausible mechanism by which
nNOS generated HNO may modify the RyR in vivo. Given the
increasingly appreciated role of nNOS in regulating SR Ca2 +
handling, one may wonder whether under conditions of in-
creased oxidative stress HNO could be the leading product of
nNOS, tonically influencing the function of the neighboring
RyR2. Again, verifying this intriguing idea is subordinated to
the possibility of effectively detecting HNO emission from
nNOS in intact myocytes.
FIG. 3. Effects of HNO donors on cardiomyocyte electro-
contraction coupling. To increase basal contractile function,
classical inotropic agents such as b-adrenergic agonists recruit
extracellular Ca2 + by opening L-type Ca2 + channels (LTCC).
This amount of Ca2 + triggers a larger Ca2 + release from the
ryanodine receptor 2 (RyR2), making more ions available to
myofilaments, thus allowing the formation of cross-bridges
between actin and myosin that ultimately generates cardiac
muscle contraction. This process is regulated by addi-
tional, regulatory myofilament proteins such as tropomyosin.
Differently from b-agonists and other cyclic adenosine
monophosphate/protein kinase A-dependent inotropic
agents, HNO does not require extracellular Ca2 + to increase
myocyte contractility. Rather, it enhances intracellular Ca2 +
cycling, enhancing the fractional release of Ca2 + from the
sarcoplasmic reticulum (SR) by opening RyR2 and by pro-
moting a faster Ca2 + re-uptake by the SR, avoiding a rise in SR
Ca2 + load that may ultimately lead to adverse effects such as
arrhythmias. This finely tuned effect of HNO on SR Ca2 +
balance is due to the fact that HNO stimulates a bigger Ca2 +
release from RyR2 but, at the same, it also favors a faster
removal of Ca2 + from the cytosol. Indeed, HNO removes the
‘‘brake-effect’’ exerted by phospholamban (PLN) on SR Ca2 + -
ATPase (SERCA2a), that is, the enzymatic activity deputed to
re-uptake Ca2 + inside the SR. Likely, HNO modifies SR Ca2 +
cycling via its interaction with highly-reactive thiols present in
several intracellular EC structures such as RyR2, PLN, and/or
SERCA2a and myofilaments with associated regulatory pro-
teins, but not LTCC. MLC1, myosin light chain 1; MHC,
myosin heavy chain. (To see this illustration in color the
reader is referred to the web version of this article at
www.liebertonline.com/ars).
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Other Actions of HNO in the Circulatory System
In concourse with its peculiar cardiac functional endow-
ments, HNO donors possess properties that may positively
affect failing hearts or may be helpful in the treatment of other
chronic cardiovascular disorders. First, one effect of AS that
was appreciated even before it was recognized as a HNO and
not a NO donor was that HNO donors are good inhibitors of
platelet aggregation (4). Further, although a cGMP-dependent
or redox-mediated mechanism is yet to be defined, HNO
donors may also serve as antithrombotic agents. In addition to
this, Fukuto’s group have shown that HNO may act as an
antioxidant via facile hydrogen-atom donation to oxidizing
radical species (an event similar to what happens with to-
copherols) and subsequent generation of NO (39), a well-
established quencher of ROS. The latter finding goes hand
in hand with studies from Naughton et al., which showed
that AS/HNO is able to induce the expression of mRNA
for heme-oxygenase-1(HO-1) in a concentration- and time-
dependent manner, which translated into increased HO-1
activity in rat H9c2 cells (51). HO-1 controls heme and iron
distribution, as such, playing a crucial physiological role in
cell survival (14). HO-1 as well as its products, CO and bili-
rubin, also have major implications in countering endothe-
lial cell damage, atherogenesis, and oxidation of low-density
lipoproteins (14). All of these effects are desirable in patients
suffering from acute or chronic coronary artery disease,
eventually leading to CHF.
HNO donors, such as IPA/NO, have also been reported to
inhibit neointimal hyperplasia by inhibiting vascular smooth
muscle cell proliferation and macrophage infiltration (70).
Concomitant with possible anti-inflammatory actions of
HNO donors are preliminary data which show that HNO
donors such as NCA (63) induce a twofold increase in active
ERK1/2 and inhibit leukemia-inhibiting factor-induced IL-6
type cytokine activation of JAK-STAT signaling (79) [which
was previously shown to be redox-sensitive (37)]. However,
in vascular settings, certain doses of IPA/NO may counter
endothelial cell proliferation and increase animal mortality
(70). This comes as no surprise, as we and others have dem-
onstrated that high levels of HNO may have pro-oxidant ef-
fects (73), as demonstrated by its exacerbating effects on
ischemia-reperfusion injury in the heart (41) or in the brain
(10). These findings reiterate the same mainstay that different
levels of ROS/RNS elicit different thiol chemistry and ulti-
mately functional outcomes. In the end, at low levels, HNO is
a mild oxidizing agent, and its interaction with highly reactive
groups unlikely exceeds the formation of reversible disulfide
bonds. This is in contrast to stronger oxidants (or high fluxes
of ROS/RNS) that may lead to an overriding oxidative
chemistry, including the formation of sulfinic and sulfonic
acid-Cys (5) and/or the modification of additional protein
residues, such as tyrosine.
A yet poorly covered, but very relevant territory of, in-
vestigation is the possibility that HNO donors may have an
antihypertrophic effect, particularly in settings such as post-
ischemic LV remodeling. Preliminary data obtained by
Ritchie’s group in neonatal rat cardiac myocytes hints to the
intriguing possibility that AS/HNO may counter angiotensin
II-induced hypertrophy in a cGMP-dependent manner (31).
While these data remain to fully validated and extended to
adult cardiac cells, the current lack of long lasting HNO do-
nors prevents us from assessing whether (and through which
mechanisms) HNO donors may prevent or retard the ship-
wreck of structure and function of hearts subjected to chronic
volume or pressure overload.
Therapeutical Potential of HNO Donors
to Treat Acute and Chronic Cardiac Disorders
For several reasons, CHF represents a ‘‘therapeutic chal-
lenge.’’ First, signaling pathways such as the b-adrenergic
receptors, which are essential for the heart to cope with in-
creased physiological demand or decreased cardiac function,
are downregulated in heart failure. Moreover, although NO
and other nitrogen-derived species such as nitrite/nitrate are
useful for unloading failing hearts, their presence may dam-
pen b-evoked increases in contractile reserve (43). Second,
inotropic agents that use intracellular cAMP levels to leverage
myocardial performance (i.e., b-agonists and phosphodies-
terase inhibitors) are deleterious in the long term. When given
chronically, these agents alter intracellular Ca2 + homeostasis,
thus making the heart more prone to potentially fatal ar-
rhythmias. Accordingly, their use in patients with CHF is
currently limited to palliative care or a bridge to transplan-
tation or mechanical assist device implantation. However, the
failing heart still requires functional support. Unfortunately,
recent clinical trials employing the most promising Ca2 +
sensitizer, levosimendan, were accompanied by increased
mortality (26). Hence, efforts are currently ongoing to convert
a ‘‘Paradise Lost’’ [the status of currently available inotropes
(11)] into a ‘‘Paradise Regained,’’ because poor contractile
function is a major functional impediment in patients with
CHF and is, in part, at the foundation of their symptoms of
congestion. A plethora of animal studies have shown the
ability of supplement antioxidants to prevent LV remodeling
and improve function in several models of CHF. However,
when translated to human CHF settings, these interventions
invariably fail or even result in increased mortality, unless the
antioxidant effect is combined with another pharmacological
activity, as is the case of the b-blocker carvedilol (22), which is
also an antioxidant. As recently stated:
‘‘Since the RyR protein complex plays a central role in Ca2 +
signaling, it is an ideal therapeutic target in heart disease. In
situations where enhanced RyR activity is desirable, a RyR2-
based therapy might include a cocktail of drugs to maintain
the correct balance between Ca2 + uptake into the SR and Ca2 +
release from the SR. In other situations where the RyR activity
is enhanced, a reduction in activity alone might be sufficient to
help rectify the imbalances in Ca2 + homeostasis. Indeed this
has already been demonstrated with the drug JTV519. The
proven cardioprotective action of this drug has established
the RyR as a viable therapeutic target and has opened the door
for the development of a new classes of drugs directed to-
wards the calcium release channel’’ (19).
On closer examination, HNO donors may reunite all these
favorable effects in one single molecule. Combined with its
unloading action, HNO’s role on SR Ca2 + cycling and myo-
filament function consign it to the status of an ‘‘inodilator.’’
This should be ideal in the treatment of decompensated
patients with CHF, at least acutely or in subchronic terms.
Conversely, for a thorough exploration of the effects of HNO
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on a chronic setting, that is, prevention of LV remodeling, we
should wait until reliable long-lasting HNO donors are
available to be used in animal models of CHF or other forms
of chronic cardiac and noncardiac diseases.
Future Directions in HNO Research
in the Cardiovascular Arena
There are many aspects of the HNO pharmacological pro-
file that warrant further, more in-depth investigation. The
most striking gap in the HNO field is that the functional im-
pact of HNO on systems other than the cardiovascular one,
or additional cellular components, is almost completely un-
known. Using a proteomics approach, an extensive modifi-
cation of mitochondrial protein thiols by AS/HNO has been
reported (64). This study suggests that HNO interacts with
mitochondria through a mechanism distinct from those of
either NO or peroxynitrite (ONOO - ). However, similar to
NO (6), HNO appears to inhibit mitochondrial respiration
through the inhibition of complexes I and II, most probably
via modification of specific cysteine residues in the proteins.
The meaning of these findings remains to be contextualized in
relevant pathophysiological settings such as ischemia-
reperfusion and CHF where HNO may exert important in-
fluences on energy production or ROS emission. Equally
important will be delineating the functional impact of HNO
on several aspects of the pulmonary and the renal systems, as
both of these are crucially involved in the onset and pro-
gression of acute and chronic cardiac diseases. Finally, al-
though HNO is capable of inducing oxidative stress, it can
also act as an antioxidant via facile hydrogen-atom donation
to oxidizing radical species (akin to tocopherol) and subse-
quent generation of NO. Significantly, the studies demon-
strated that the pro-oxidant effects were performed at high
levels of HNO, whereas the antioxidant properties were ob-
served at much lower concentrations. Future studies should
address whether the presence of endogenous or exogenously
applied HNO donors can result in beneficial effects when high
tissue oxidative stress is present in the context of pathophy-
siologically relevant conditions in which pro-inflammatory
signaling pathways are at play.
Concluding Remarks
Among all possible redox-sensitive keys harbored by
structures belonging to the EC coupling machinery, HNO is
likely able to interact and modify those that have a specific
spatial location and pKa, thus enlisting a biological response.
Therefore, to fully understand the effect of HNO on cardio-
vascular mechanics, it will be necessary to fully unearth
where all these ‘‘keys’’ are situated. Further, we also have to
establish whether (and to what extent) HNO signaling inter-
act, or perhaps interfere, with other thiol-based ROS/
RNS-induced modifications such as S-nitrosylation. Equally
relevant would be to fully dissect the mechanisms whereby
HNO action is terminated, for example, through GSH, thior-
edoxin system, etc. This is another important avenue for
future studies that will presumably teach us more about
when HNO effects cease being beneficial and start becoming
detrimental.
From a practical point of view, ongoing clinical trials are
evaluating whether a redox-based approach to improve de-
teriorated myocardial function, similar to the one granted by
HNO, is a valid alternative or a useful addition to what are
currently known as cardiac inotropes.
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Abbreviations Used
AS¼Angeli’s salt
BH4 ¼ tetrahydrobiopterin
cAMP¼ cyclic adenosine monophosphate
cGMP¼ cyclic guanosine monophosphate
CGRP¼ calcitonin gene-related peptide
CHF¼ congestive heart failure
CK¼ creatine kinase
CO¼ carbon monoxide
DEA/NO¼diethylamine/NO complex
EC¼ excitation-contraction
EDRF¼ endothelium-derived relaxing factor
GAPDH¼ glyceraldehyde 3-phosphate
dehydrogenase
GSH¼ glutathione
GSNO¼ s-nitrosoglutathione
HNO¼nitroxyl or nitrosyl hydride
HO-1¼heme-oxygenase-1
H2S¼hydrogen sulfide
IPA¼ isopropylamine
LTCC¼L-type Ca2+ channels
LV¼ left ventricular
MHC¼myosin heavy chain
mKATP ¼mitochondrial K(ATP) channel
MLC1¼myosin light chain 1
NCA¼ 1-nitrosocyclohexyl acetate
NH2OH¼hydroxylamine
nNOS¼neuronal nitric oxide synthase
NO¼nitric oxide
NOHA¼NG-hydroxy-L-arginine
NOS¼nitric oxide synthase
pKa¼ acid dissociation constant
PKA¼protein kinase A
PLN¼phospholamban
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
RyR2¼ ryanodine receptor 2
SERCA2a¼Ca2+-ATPase
sGC¼ soluble guanylyl cyclase
SNP¼ sodium nitroprusside
SOD¼ superoxide dismutase
SR¼ sarcoplasmic reticulum
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